Circulating microRNAs as biomarkers in progressive multiple sclerosis

Abstract

Background:

In multiple sclerosis (MS), microRNA (miRNA) dysregulation is mostly reported in different immune cells, but less information is available on circulating miRNAs that exert strong biomarker potential due to their exceptional stability in body fluids.

Objective:

The aim of this study was to profile expression of circulating miRNAs in primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS) and assess their association with neurological worsening.

Methods:

The expressions of 84 different miRNAs were profiled in serum of 83 subjects (62 MS and 21 controls) using miScript miRNA techniques. First, they were screened on 18 PPMS and 10 controls; thereafter, 10 most aberrantly expressed miRNAs were validated on a larger cohort.

Results:

In comparison with controls, upregulation of miR-191-5p was found in both progressive MS subtypes, while miR-376c-3p was overexpressed only in PPMS. Additionally, upregulation of miR-128-3p and miR-24-3p was detected in PPMS when compared to controls and SPMS. Progression index correlated with miR-128-3p in PPMS and miR-375 in SPMS.

Conclusion:

We detected overexpression of four miRNAs that have not been previously associated with progressive forms of MS. The increased expression of circulating miR-191-5p seems to be associated with progressive forms of MS, while miR-128-3p seems to be associated mostly with PPMS.

Keywords

Multiple sclerosis PPMS SPMS biomarkers circulating microRNA miR-128-3p miR-376c-3p miR-191-5p miR-24-3p

Get full access to this article

View all access options for this article.

References

Huntzinger

Izaurralde

. Gene silencing by microRNAs: Contributions of translational repression and mRNA decay. Nat Rev Genet 2011; 12(2): 99–110.

Kosaka

Yoshioka

Hagiwara

. Trash or treasure: Extracellular microRNAs and cell-to-cell communication. Front Genet 2013; 4: 173.

Pauley

Cha

Chan

EKL

. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009; 32(3–4): 189–194.

Gandhi

. miRNA in multiple sclerosis: Search for novel biomarkers. Mult Scler 2015; 21: 1095–1103.

Fenoglio

Ridolfi

Cantoni

. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Mult Scler 2013; 19(14): 1938–1942.

Gandhi

Healy

Gholipour

. Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol 2013; 73(6): 729–740.

Siegel

Mackenzie

Chaplin

. Circulating microRNAs involved in multiple sclerosis. Mol Biol Rep 2012; 39(5): 6219–6225.

Søndergaard

Hesse

Krakauer

. Differential microRNA expression in blood in multiple sclerosis. Mult Scler 2013; 19(14):1849–1857.

Zhang

Cheng

Cui

. MicroRNA-155 modulates Th1 and Th17 cell differentiation and is associated with multiple sclerosis and experimental autoimmune encephalomyelitis. J Neuroimmunol 2014; 266(1–2): 56–63.

10.

Kacperska

Jastrzebski

Tomasik

. Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity—Preliminary study. J Mol Neurosci 2015; 56(1): 154–163.

11.

Celsi

Pizzo

Brini

. Mitochondria, calcium and cell death: A deadly triad in neurodegeneration. Biochim Biophys Acta 2009; 1787(5): 335–344.

12.

Romme Christensen

Bornsen

Ratzer

. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS ONE 2013; 8(3): e57820.

13.

Romme Christensen

Ratzer

Bornsen

. Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial. Neurology 2014; 82(17): 1499–1507.

14.

Hauser

Comi

Hartung

H-P

. Efficacy and safety of ocrelizumab in relapsing multiple sclerosis—results of the interferon-beta-1a-controlled, doubleblind, Phase III OPERA I and II studies. Mult Scler 2015; 23(S11): 61–62.

15.

Montalban

Hemmer

Rammohan

. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis—Results of the placebo-controlled, double-blind, Phase III ORATORIO study. Mult Scler 2015; 21(S1): 781–782.

16.

McDonald

Compston

Edan

. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1): 121–127.

17.

Kurtzke

. On the evaluation of disability in multiple sclerosis. 1961. Neurology 1998; 50(2): 317 and 9 pages following.

18.

Wylie

Shelton

Choudhary

. A novel mean-centering method for normalizing microRNA expression from high-throughput RT-qPCR data. BMC Res Notes 2011; 4: 555.

19.

Sievers

Meira

Hoffmann

. Altered microRNA expression in B lymphocytes in multiple sclerosis: Towards a better understanding of treatment effects. Clin Immunol 2012; 144(1): 70–79.

20.

Guerau-de-Arellano

Smith

Godlewski

. Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain 2011; 134(Pt 12): 3578–3589.

21.

Smirnova

Grafe

Seiler

. Regulation of miRNA expression during neural cell specification. Eur J Neurosci 2005; 21(6): 1469–1477.

22.

Adlakha

Saini

. Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128. Mol Cancer 2014; 13: 33.

23.

Tiribuzi

Crispoltoni

Porcellati

. miR128 up-regulation correlates with impaired amyloid beta(1-42) degradation in monocytes from patients with sporadic Alzheimer’s disease. Neurobiol Aging 2014; 35(2): 345–356.

24.

Saba

Goodman

Huzarewich

. A miRNA signature of prion induced neurodegeneration. PLoS ONE 2008; 3(11): e3652.

25.

Abu-Elneel

Liu

Gazzaniga

. Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics 2008; 9(3): 153–161.

26.

Fayyad-Kazan

Hamade

Rouas

. Downregulation of microRNA-24 and -181 parallels the upregulation of IFN-gamma secreted by activated human CD4 lymphocytes. Hum Immunol 2014; 75(7): 677–685.

27.

Vlachos

Kostoulas

Vergoulis

. DIANA miRPath v.2.0: Investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res 2012; 40(Web Server issue): W498–W504.

28.

Bublil

Yarden

. The EGF receptor family: Spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19(2): 124–134.

29.

Wosik

Antel

Kuhlmann

. Oligodendrocyte injury in multiple sclerosis: A role for p53. J Neurochem 2003; 85(3): 635–644.

30.

Giacalone

Clarelli

Osiceanu

. Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. Mult Scler 2015; 21: 1431–1442.

31.

Minagar

Zhang

. Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: Correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b. Neurol Res 2012; 34(6): 611–618.

32.

Nagpal

Kulshreshtha

. miR-191: An emerging player in disease biology. Front Genet 2014; 5: 99.

33.

Hemmer

Kerschensteiner

Korn

. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol 2015; 14(4): 406–419.

34.

Kumar

Dezso

MacKenzie

. Circulating miRNA biomarkers for Alzheimer’s disease. PLoS ONE 2013; 8(7): e69807.

35.

Jovicic

Roshan

Moisoi

. Comprehensive expression analyses of neural cell-type-specific miRNAs identify new determinants of the specification and maintenance of neuronal phenotypes. J Neurosci 2013; 33(12): 5127–5137.

36.

Liu

Wang

. A reciprocal antagonism between miR-376c and TGF-beta signaling regulates neural differentiation of human pluripotent stem cells. FASEB J 2014; 28(11): 4642–4656.

37.

Nadeem

. MicroRNA-376c impairs transforming growth factor-beta and nodal signaling to promote trophoblast cell proliferation and invasion. Hypertension 2013; 61(4): 864–872.

38.

Balasa

Bajko

Maier

. The dual role of transforming growth factor beta in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. Rom J Neurol 2014; 13(3): 103–107.

39.

Meoli

Grant

. TGF-beta signaling is altered in the peripheral blood of subjects with multiple sclerosis. J Neuroimmunol 2011; 230(1–2): 164–168.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.24 MB